ORIC Pharmaceuticals Touts Positive Efficacy, Safety Data From Early-Stage Prostate Cancer Candidate, Raises Capital

Why did Fed lift Wells Fargo's asset cap? How will doubled steel tariffs affect US prices? What impact will Amazon's $10B AI investment have? Why is Apple facing AI rollout delays in China? How are US tariffs affecting private sector hiring? What caused Robinhood's shares to hit a record high? Why is Meta investing in nuclear power for AI?

ORIC Pharmaceuticals Touts Positive Efficacy, Safety Data From Early-Stage Prostate Cancer Candidate, Raises Capital

benzinga.com/general/biotech/25/05/45674091/oric-pharmaceuticals-touts-positive-efficacy-safety-data-from-early-stage-prostate-cancer-candida

ORIC Pharmaceuticals Inc. (NASDAQ:ORIC) released preliminary efficacy and safety data on Wednesday from its ongoing Phase 1b trial of once daily ORIC-944 in combination with androgen receptor (AR) inhibitors in patients with metastatic castration-resistant prostate cancer…

This story appeared on benzinga.com, 2025-05-29 15:15:54.